September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose positron emission tomography). This acquisition includes the license to market GE Healthcare’s SteriPET (FDG) imaging agent in Italy.
Stefano Buono, CEO of AAA, said: “This acquisition is in line with AAA’s growth strategy of further consolidating our position as a leading pan-European nuclear diagnostics company, alongside exploring additional product pipeline opportunities and avenues for expansion in the United States and outside Europe.”
“We believe that this transaction will enable AAA Italy to benefit from economies of scale from which we can continue providing quality products and services at reduced costs in a market that has been experiencing a reduction of FDG’s price over the last years,” added Enrico De Maria, CEO of AAA Italy.
AAA’s diagnostic PET product is Gluscan, its branded FDG PET imaging agent. Gluscan assists in the diagnosis of serious diseases, primarily in oncology, by assessing glucose metabolism. The company has 13 PET production facilities based in France, Germany, Italy, Poland, Portugal and Spain. With this acquisition AAA intends to broaden its presence in the Italian PET market and add to its existing production capacity and portfolio.
For more information: www.adacap.com
July 30, 2024 
